Viking Therapeutics, Inc. (VKTX)
28.67
+0.94
(+3.39%)
USD |
NASDAQ |
Oct 09, 12:31
Viking Therapeutics EPS Diluted (Quarterly) : -1.101 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -1.101 |
| March 31, 2026 | -1.37 |
| December 31, 2025 | -1.383 |
| September 30, 2025 | -0.8083 |
| June 30, 2025 | -0.5847 |
| March 31, 2025 | -0.4072 |
| December 31, 2024 | -0.3181 |
| September 30, 2024 | -0.2249 |
| June 30, 2024 | -0.2016 |
| March 31, 2024 | -0.2644 |
| December 31, 2023 | -0.2458 |
| September 30, 2023 | -0.2257 |
| June 30, 2023 | -0.1942 |
| March 31, 2023 | -0.2493 |
| December 31, 2022 | -0.2554 |
| September 30, 2022 | -0.2062 |
| June 30, 2022 | -0.2269 |
| March 31, 2022 | -0.208 |
| December 31, 2021 | -0.1607 |
| September 30, 2021 | -0.1698 |
| June 30, 2021 | -0.1974 |
| March 31, 2021 | -0.1873 |
| December 31, 2020 | -0.1502 |
| September 30, 2020 | -0.1279 |
| June 30, 2020 | -0.132 |
| Date | Value |
|---|---|
| March 31, 2020 | -0.1339 |
| December 31, 2019 | -0.1033 |
| September 30, 2019 | -0.0796 |
| June 30, 2019 | -0.1067 |
| March 31, 2019 | -0.0686 |
| December 31, 2018 | -0.0734 |
| September 30, 2018 | -0.1078 |
| June 30, 2018 | -0.1264 |
| March 31, 2018 | -0.1022 |
| December 31, 2017 | -0.14 |
| September 30, 2017 | -0.22 |
| June 30, 2017 | -0.21 |
| March 31, 2017 | -0.23 |
| December 31, 2016 | -0.18 |
| September 30, 2016 | -0.20 |
| June 30, 2016 | -0.22 |
| March 31, 2016 | -0.40 |
| December 31, 2015 | -0.56 |
| September 30, 2015 | -0.53 |
| June 30, 2015 | -1.07 |
| March 31, 2015 | -1.40 |
| June 30, 2014 | -2.33 |
| March 31, 2014 | -0.0059 |
| June 30, 2013 | -0.0023 |
| March 31, 2013 | -0.0005 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 4.310 |
| Eli Lilly & Co. | 7.939 |
| Regeneron Pharmaceuticals, Inc. | 12.23 |
| Amgen, Inc. | 4.366 |
| Ironwood Pharmaceuticals, Inc. | 0.3068 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -128.02M |
| Total Expenses (Quarterly) | 128.02M |
| Enterprise Value | 2.737B |
| Earnings Yield | -16.26% |
| Normalized Earnings Yield | -16.26 |